DANBURY, Conn.--(BUSINESS WIRE)--IMS Health has acquired DecisionView, a San Francisco-based software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials around the world. DecisionView offers its clients an innovative suite of decision support tools to improve the speed, efficiency and performance of clinical trial planning and management.
IMS will integrate its market-leading health outcomes, provider and anonymized patient data assets with DecisionView’s advanced optimization technology, predictive analytics and performance data gathered from more than 1,200 clinical studies across 90+ countries. This combination will enable clinical trial sponsors and research organizations, for the first time, to base vital site selection and patient enrollment decisions on global, real-world data and benchmarks.
“Today, the clinical trial planning and enrollment process is inefficient due to the lack of real-world data and analytics in trials management and decision making,” says Andrew Kress, senior vice president, IMS Healthcare Value Solutions. “Approximately 90 percent of clinical trials don’t finish on time, with trial enrollment cited as the leading cause of the delays. Through this acquisition, we will enhance clinical trial productivity – transforming the way patient studies are planned and executed.”
DecisionView becomes part of IMS’s Healthcare Value Solutions business, which connects healthcare stakeholders through real-world evidence to demonstrate the value of medicines, enhance quality and drive improved results. IMS Healthcare Value Solutions is focused on health economics and outcomes research, government solutions, payer and provider solutions, and clinical trial optimization services that include patient enrollment and protocol feasibility.
“We’re very excited to join IMS’s team,” says Linda Drumright, DecisionView president and CEO. “Our clients recognize the need for more data and analytics to guide their clinical trial enrollment and performance management activities – and they’re actively looking for innovative solutions. The combination of DecisionView and IMS is powerful and elevates our value to clients by opening up a whole new set of possibilities for clinical trial decision-making.”
DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView’s flagship solution, StudyOptimizer®, is a web-based solution that helps clinical trial organizations plan, forecast and track patient enrollment. DecisionView Enrollment BenchmarksTM aggregate cross-industry performance data from clinical trials that have completed enrollment, providing insight to enable more realistic planning and forecasting. DecisionView products are used by 8 of the top 10 global pharmaceutical companies, and have been used on clinical studies with over 450,000 subjects enrolled in 17 different therapeutic areas. For additional information about DecisionView, go to http://www.decisionview.com.
About IMS Health
IMS Health is a leading provider of information, services and technology for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and software platforms to help clients better understand the performance and value of medicines. With a presence in 100+ countries and more than 55 years of industry experience, IMS serves leading decision makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at http://www.imshealth.com.